PSY5 Comparing Brentuximab Vedotin Overall Survival Data to Standard of Care in Patients With Relapsed/Refractory Hodgkin Lymphoma (HL) Post-Autologous Stem Cell Transplant (ASCT)
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1728
https://www.valueinhealthjournal.com/article/S1098-3015(12)03441-9/fulltext
Title :
PSY5 Comparing Brentuximab Vedotin Overall Survival Data to Standard of Care in Patients With Relapsed/Refractory Hodgkin Lymphoma (HL) Post-Autologous Stem Cell Transplant (ASCT)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03441-9&doi=10.1016/j.jval.2012.08.1728
First page :
A509
Section Title :
Systemic Disorders/Conditions
Open access? :
No
Section Order :
1219